Natriumjodid (I-131) Ge Healthcare (Sodium Iodide (131i))

Sodium Iodide I-131 is absorbed by thyroid follicular cells via the sodium‑iodide symporter. Inside the gland, the isotope emits beta particles that cause localized cellular damage, while gamma emissions enable external imaging. This selective uptake provides targeted therapy and diagnostic information without affecting surrounding tissues.

The prescribed dose of Natriumjodid (I-131) is determined by the treating physician based on the specific indication, patient weight, thyroid size, and intended therapeutic goal. Dosing is individualized and should follow the prescriber’s written order and local radiation safety guidelines.

Radioactive iodine is generally contraindicated in pregnancy because it can cross the placenta and affect fetal thyroid development. Breastfeeding should be paused for a period recommended by the prescribing physician to avoid iodine transfer to the infant. Consultation with a specialist is essential before use in these situations.

To request Natriumjodid (I-131), submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with non‑radioactive therapies such as antithyroid drugs or surgical removal, Natriumjodid (I-131) offers a non‑invasive, targeted approach that can both image and ablate thyroid tissue in a single administration. It avoids the risks of surgery and provides precise dosing, but requires adherence to radiation safety protocols.

Natriumjodid (I-131) should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight, and physical damage. Follow local regulations for handling radioactive materials, including proper labeling and disposal of any waste.

The product is administered orally, usually as a single dose in capsule or liquid form, under the supervision of a qualified physician. Patients may be instructed to fast before and after dosing to optimize thyroid uptake, and radiation safety guidelines are observed for both patient and staff.

Serious risks include salivary gland inflammation, severe allergic reactions, bone marrow suppression, and, rarely, secondary malignancies due to radiation exposure. Patients should be monitored for signs of these events, and any severe symptoms should prompt immediate medical evaluation.

Contraindications include pregnant women, nursing mothers (unless discontinued for the recommended interval), patients with severe iodine allergy, and individuals with uncontrolled thyroiditis. Additionally, patients unable to comply with radiation safety measures should not receive this radiopharmaceutical.